BeiGene Ltd logo

BeiGene Ltd - Class A

SHSE:688235 (Cayman Islands)   Class A
¥ 122.23 (+0.18%) Jun 20
At Loss
P/B:
4.79
Market Cap:
¥ 122.73B ($ 16.90B)
Enterprise V:
¥ 109.95B ($ 15.14B)
Volume:
54.29M
Avg Vol (2M):
1.38M
Trade In:
Volume:
54.29M
At Loss
Avg Vol (2M):
1.38M

Business Description

Description
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Name Current Vs Industry Vs History
Cash-To-Debt 2.63
Equity-to-Asset 0.59
Debt-to-Equity 0.32
Debt-to-EBITDA -1.06
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.93
Distress
Grey
Safe
Beneish M-Score -2.2
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 28.01
9-Day RSI 37.74
14-Day RSI 41.65
6-1 Month Momentum % -8.19
12-1 Month Momentum % 13.87

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 2.08
Quick Ratio 1.84
Cash Ratio 1.48
Days Inventory 310.37
Days Sales Outstanding 45.22
Days Payable 262.6

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.5
Shareholder Yield % -1.11

Financials (Next Earnings Date:2024-08-02 Est.)

SHSE:688235's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

BeiGene Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil ¥) 19,907.639
EPS (TTM) (¥) -4.206
Beta 0
Volatility % 47.31
14-Day RSI 41.65
14-Day ATR (¥) 4.105231
20-Day SMA (¥) 124.8485
12-1 Month Momentum % 13.87
52-Week Range (¥) 98.5 - 163.88
Shares Outstanding (Mil) 1,369.58

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BeiGene Ltd Filings

Filing Date Document Date Form
No Filing Data

BeiGene Ltd Stock Events

Financials Calendars
Event Date Price(¥)
No Event Data

BeiGene Ltd Frequently Asked Questions

What is BeiGene Ltd(SHSE:688235)'s stock price today?
The current price of SHSE:688235 is ¥122.23. The 52 week high of SHSE:688235 is ¥163.88 and 52 week low is ¥98.50.
When is next earnings date of BeiGene Ltd(SHSE:688235)?
The next earnings date of BeiGene Ltd(SHSE:688235) is 2024-08-02 Est..
Does BeiGene Ltd(SHSE:688235) pay dividends? If so, how much?
BeiGene Ltd(SHSE:688235) does not pay dividend.

Press Release

Subject Date
No Press Release